A Phase 2, Double-Blind, Randomized, Dose-Ranging Trial Of Reldesemtiv In Patients With ALS

Autor: Gary L. Pattee, Ashley Whyte-Rayson, Andrew A. Wolff, Jeremy M. Shefner, Lisa Meng, Jesus S. Mora, Lorne Zinman, Steve Vucic, Terry Heiman-Patterson, Stephen J. Kolb, James Caress, Bettina M. Cockroft, Carlayne E. Jackson, Timothy M. Miller, Michael D. Weiss, Ghazala Hayat, Shumaila Sultan, Benjamin Rix Brooks, Daragh Heitzman, Tuan Vu, Merrilee Needham, Dianna Quan, Genevieve Matte, Shafeeq Ladha, Orla Hardiman, Fady I. Malik, Zachary Simmons, Wendy Johnston, Christen Shoesmith, Namita Goyal, Erik P. Pioro, James Wymer, David Schultz, Leonard H. van den Berg, Cynthia Bodkin, Lawrence Korngut, Jeffrey Statland, Michael Pulley, Bjorn Oskarsson, Chafic Karam, Angela Genge, Matthew C. Kiernan, Jenny Wei, Annie Dionne, Jinsy A. Andrews, Noah Lechtzin, Stephen A. Goutman, Andrea Swenson, Dominic B. Fee, Kerri Schellenberg, Robert D. Henderson, Kourosh Rezania, Stacy A. Rudnicki
Rok vydání: 2020
Předmět:
Zdroj: Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration. 22:287-299
ISSN: 2167-9223
2167-8421
DOI: 10.1080/21678421.2020.1822410
Popis: To evaluate safety, dose response, and preliminary efficacy of reldesemtiv over 12 weeks in patients with amyotrophic lateral sclerosis (ALS). Methods: Patients (≤2 years since diagnosis) with slow...
Databáze: OpenAIRE